

A randomised controlled trial of the combined use of paracetamol and ibuprofen to treat febrile children

Submission date 30/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 30/09/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 10/04/2012	Condition category Signs and Symptoms	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr MDS Erlewyn-Lajeunesse

Contact details

C/O Research & Effectiveness Department
Level 1, The Old Building
Bristol Royal Infirmary
Malborough Street
Bristol
United Kingdom
BS2 8HW
+44 (0)117 928 3473
r&eoffice@ubht.swest.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0264160475

Study information

Scientific Title

Study objectives

To ascertain whether using paracetamol and ibuprofen in combination is better than using either alone when treating children with fever in the setting of an emergency department.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Fever

Interventions

Unblinded but RCT. Children presenting at the children's emergency department with fever will be invited to take part. Those with a temperature greater than or equal to 38.0 degrees C will be enrolled subject to consent.

Subjects will be allocated at random to one of three treatment arms:

1. Ibuprofen alone (5mg/kg)
2. Paracetamol alone (15 mg/kg)
3. Ibuprofen (5mg/kg) & Paracetamol (15 mg/kg)

Subjects will receive a single treatment. Temperature will be recorded at dosage, 1 hour later and if still in the department, 2 hours later.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

The child's temperature one hour after study antipyretics

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/10/2004

Completion date

04/04/2005

Eligibility**Key inclusion criteria**

Children presenting in the BRI children's emergency department with fever. Inclusion criteria:

1. Age 6 months - 16 years
2. Children with a temperature of 38.0 degrees C or more will be eligible

Participant type(s)

Patient

Age group

Child

Lower age limit

6 Months

Upper age limit

16 Years

Sex

Both

Target number of participants

120

Key exclusion criteria

1. Those admitted directly to resuscitation by ambulance or those transferred there following initial clinical assessment
2. Those eligible for recruitment in any other study running concurrently or those who have been

recruited to a simultaneous study of children's fever

3. Prior administration that will interfere with randomisation: paracetamol within the last six hours or ibuprofen within the last six hours

4. Allergy to either study drug

5. Likely dehydration, cellulitis or skin infection, concomitant warfarin or heparin, chronic illness likely to interfere with drug metabolism (kidney or liver disease), immunosuppression, HIV+, concomitant chemo or radiotherapy, organ or bone marrow transplant recipient, immunosuppressive therapy in the last three months

Date of first enrolment

01/10/2004

Date of final enrolment

04/04/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

C/O Research & Effectiveness Department

Bristol

United Kingdom

BS2 8HW

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)

Sponsor details

The Department of Health

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Government

Funder Name

United Bristol Healthcare NHS Trust (UK)

Funder Name

NHS R&D Support Funding (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2006		Yes	No